...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Thoughts on ZCC

KOO - In addition to what tada stated, I believe ZEL has the IP so they could sell ZEL and keep the Royalty Preferreds in ZCC or they could shift some of the IP to ZCC and sell the rest within ZEL or start another entity and shift some IP to it and sell it and keep the remainder in ZEL within ZCC ar any other number of actions they want to make whatever deal the parties would want.

Share
New Message
Please login to post a reply